Skip to content

Efficacy and Safety of Low-Dose Esketamine Combined With Target-Controlled Infusion of Propofol for Painless Gastroenteroscopy and Polypectomy

Efficacy and Safety of Low-Dose Esketamine Combined With Target-Controlled Infusion of Propofol for Painless Gastroenteroscopy and Polypectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041038
Enrollment
Unknown
Registered
2020-12-16
Start date
2020-12-09
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain

Interventions

experimental group:Propofol/Esketamine
control group:Propofol/Fentanyl

Sponsors

Tianjin Union Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Subject's American Society of Anesthesiologists physical status is I-III. 2. Subject has no symptoms of allergy to anesthetics. 3. Subject has no contraindications for gastrointestinal endoscopy. 4. Subject has given written informed consent to participate.

Exclusion criteria

Exclusion criteria: 1. Subject's BMI 30; 2. Subject has poorly controlled or untreated hypertension; 3. Subject has severe ischemic heart disease; 4. Subject is an untreated or undertreated patient with hyperthyroidism; 5. Subject has used drugs that affect their central nervous system; 6. Subject has mental illness; 7. Subject has epilepsy; 8. Subject has a history of chronic pain; 9. Subject is pregnant or breast-feeding.

Design outcomes

Primary

MeasureTime frame
Cumulative propofol Consumption;

Secondary

MeasureTime frame
The incidence of adverse events in pulmonary and circulatory systems;The Times of the patients motion reaction during operation;The satisfaction of the endoscopist and patient;Time of recovery, PACU and discharge from hospital;

Countries

China

Contacts

Public ContactYang Tao

Tianjin Union Medical Center

yangtao@nankai.edu.cn+86 18920802290

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026